About Altrartis Therapeutics
Altrartis Therapeutics is a therapeutics company based in New York. A U.S. patent assigned to it covers a composition that combines psilocybin or psilocin with MDMA. The patent describes the composition as a treatment for diseases tied to serotonin receptors.
Florian Brand is the chief executive officer and a director. Lars Christian Wilde is a director. The patent is U.S. 12,708,635 B2, and it names Robert Fletcher Roscow of Longmont, Colorado, as inventor. The company's home page carries a short mission line and a privacy policy.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Oct 22, 2026 | $10,999,977fully sold | 11 | $999K | EquityRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Altrartis Therapeutics
Altrartis Therapeutics is a New York drug developer. It is the assignee of a U.S. patent on a composition that pairs psilocybin or psilocin with MDMA. The patent describes the composition as a treatment for conditions tied to serotonin receptors.
What the product does
Claim 1 of the patent covers a composition of psilocybin or psilocin, MDMA and a pharmaceutically acceptable carrier. The claim requires the 5-HT2A serotonin receptor to be activated to about the same level as with psilocybin or psilocin alone. The patent has nine claims in all.
Progress so far
The international application was filed on September 18, 2021. Priority runs back to a provisional application filed on September 18, 2020. The application was published as US 2023/0346811 on November 2, 2023. It now stands as U.S. Patent 12,708,635 B2, with Altrartis Therapeutics named as assignee.
We wrote this summary from public statements by Altrartis Therapeutics and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Altrartis Therapeutics's Form D filed Oct 22, 2026.